Press Release

The study will evaluate the safety, tolerability, and ability of 18F-OP-801 to cross the blood-brain barrier and selectively target neuroinflammation in individuals with amyotrophic lateral sclerosis, Alzheimer’s disease, multiple sclerosis and Parkinson’s disease Preliminary data expected in 1H 2024 REDWOOD CITY, Calif., February 22, 2024 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new … Read more

REDWOOD CITY, Calif., February 14, 2024 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced that members of its senior management team will participate in two upcoming investor conferences. Conference Details:  BIO CEO & Investor Conference … Read more

REDWOOD CITY, Calif., January 4, 2024 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the appointment of Mehdi Paborji, Ph.D., as Senior Vice President of Technical Operations. Dr. Paborji will oversee technical operations, CMC, and … Read more

REDWOOD CITY, Calif., November 20, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced that members of its senior management team will participate in two upcoming ophthalmology conferences. Conference Details: BTIG 3rd Annual Ophthalmology Day  … Read more

Open-label study will evaluate the safety and efficacy of chronic D-4517.2 dosing in patients with wet age-related macular degeneration (wet AMD) or diabetic macular edema (DME) Favorable safety and tolerability results from Phase 1 and Phase 2 single dose studies of D-4517.2 support initiation of chronic dosing study Preliminary data expected in 1H 2024   … Read more

REDWOOD CITY, Calif., October 9, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the appointment of Sakura Minami, Ph.D., as Vice President of Translational Medicine and Nonclinical Development and Sarah Thayer as Head … Read more

Data demonstrated that ASH41020, a novel CSFR1 tyrosine kinase inhibitor ‘dendranib’, directs macrophage polarization toward the anti-inflammatory M2 phenotype ASH41020 treatment lessened disease severity in a preclinical model of multiple sclerosis (MS) to a similar extent to fingolimod, an approved MS treatment Study suggests ASH41020 is a potent anti-inflammatory and immunomodulatory agent that warrants further … Read more

Data will showcase anti-inflammatory and immunomodulatory effects of ASH41020, a novel CSFR1 tyrosine kinase inhibitor ‘dendranib’, in a mouse model of multiple sclerosis REDWOOD CITY, Calif., August 15, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing a new class of nanomedicine therapeutics, today announced a poster presentation of preclinical data on ASH41020, its new … Read more

REDWOOD CITY, Calif., May 31, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the appointments of Paul E. Cayer as Chief Financial Officer and Omega Therapeutics President and CEO, Mahesh Karande to the … Read more

Data demonstrated that a single oral dose of D-4517.2 significantly reduced choroidal neovascularization (CNV) lesions to a level comparable to D-4517.2 delivered subcutaneously and Aflibercept administered intravitreally at the same mass dose in a laser-induced CNV mouse model  Findings from a second preclinical study in a VLDLR−/− mouse model demonstrated oral and subcutaneous administration of … Read more